Biological Trace Element Research

, Volume 47, Issue 1–3, pp 117–123 | Cite as

Lipid peroxidation products, and vitamin and trace element status in patients with cancer before and after chemotherapy, including adriamycin

A preliminary study
  • Michel Faber
  • Charles Coudray
  • Hassan Hida
  • Mireille Mousseau
  • Alain Favier
Part III Cancer and Immunity

Abstract

Adriamycin is a potent chemotherapeutic agent used in the treatment of human neoplastic diseases. A major side effect limiting the use of this drug is its toxic effect on the heart. Several hypotheses have been proposed to explain the cardiotoxicity of Adriamycin. However, the most plausible hypothesis seems to be the reduction of Adriamycin and free radical production, which induces lipid peroxidation and oxidative damages in the heart.

We have thus undertaken this preliminary study to investigate Adriamycin-induced lipid peroxidation by the measurement of plasma thiobarbituric acid reactant materials and antioxidant systems, namely glutathione content, glutathione peroxidase activity, and vitamin and trace element status, in patients with cancer before and after chemotherapy, including Adriamycin.

The concentration of thiobarbituric acid reactant materials in plasma of patients with cancer was higher than in controls and was further increased after chemotherapy. Blood glutathione and plasma glutathione peroxidase activity, as well as plasma zinc and selenium in patients with cancer, were decreased, but not further modified by chemotherapy. However, only zinc and selenium levels reached a significant level. In contrast, plasma vitamin E and β-carotene levels were not significantly increased in patients with cancer. Finally, plasma vitamin A and copper levels were not modified either in patients with cancer or by chemotherapy.

Index Entries

Cancer Adriamycin lipid peroxidation trace elements, antioxidants 

Abbreviations

ADR

Adriamycin

GSH

reduced glutathione

GSSG

oxidized glutathione

GPx

glutathione peroxidase

OHP

organic hydroperoxides

TBARMs

thiobarbituric acid reactant materials

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    R. C. Young, R. E. Ozols, and C. E. MeyersN. Engl. J. Med. 305, 139 (1981).PubMedCrossRefGoogle Scholar
  2. 2.
    R. E. Ozols, R. C. Young, and J. L. SpeyerCancer Res. 42, 4265 (1982).PubMedGoogle Scholar
  3. 3.
    S. Ragajopalan, P. M. Politi, B. Sinha, and C. E. MeyersCancer Res. 48, 4766 (1988).Google Scholar
  4. 4.
    R. D. Olson, R. C. Boerth, J. G. Gerber, and A. S. NiesLife Sci. 29, 1393 (1981).PubMedCrossRefGoogle Scholar
  5. 5.
    C. Winterbourn, G. F. Vile, and H. P. MonteiroFree Radic. Res. Commun. 12–13, 107 (1991).PubMedGoogle Scholar
  6. 6.
    K. Hermann, and S. HelmutExperientia 37, 1233 (1981).CrossRefGoogle Scholar
  7. 7.
    K. Takahashi, T. Mayumi, and T. KishiChem. Pharm. Bull. 35, 4626 (1978).Google Scholar
  8. 8.
    J. C. Schisselbauer, M. Crescimanno, N. D’Alessandro, M. Clapper, S. Toulmond, H. Tapiero, and K. D. TewCancer Commun. 1, 133 (1989).PubMedGoogle Scholar
  9. 9.
    M. J. Richard, B. Portal, J. Meo, C. Coudray, A. Hadjian, and A. FavierClin. Chem. 38, 704 (1992).PubMedGoogle Scholar
  10. 10.
    R. L. Heath, and A. L. TappelAnal. Biochem. 76, 184 (1976).PubMedCrossRefGoogle Scholar
  11. 11.
    W. A. Günzler, H. Kremers, and L. FloheZ. Klin. Chem. Klin. Biochem 10, 444 (1974).Google Scholar
  12. 12.
    T. P. M. Akerboom, and H. SiesMethods Enzymol. 77, 373 (1981).PubMedGoogle Scholar
  13. 13.
    J. Arnaud, S. Fortis, S. Blachier, D. Kia, and A. FavierJ. Chromatogr. 572, 103 (1991).PubMedCrossRefGoogle Scholar
  14. 14.
    J. Arnaud, J. Bellanger, P. Chappuis, A. Favier, and M. GalliotAnn. Biol. Clin. 43, 297 (1985).Google Scholar
  15. 15.
    J. Arnaud, J. Bellanger, F. Bienvenu, P. Chappuis, and A. FavierAnn. Biol. Clin. 44, 77 (1986).Google Scholar
  16. 16.
    J. Arnaud, A. Prual, P. Preziosi, A. Favier, and S. HercbergJ. Trace Element Electrolytes Health Dis. 7, 199–204 (1993).Google Scholar
  17. 17.
    E. A. Lefrak, J. Pitha, S. Rosenheim, and J. A. GottliebCancer 32, 302 (1973).PubMedCrossRefGoogle Scholar
  18. 18.
    R. A. Minow, R. S. Benjamin, and J. A. GottliebCancer Chemotherapy Rep. 6, 195 (1975).Google Scholar
  19. 19.
    S. NeidelProg. Med. Chem. 16, 151 (1979).CrossRefGoogle Scholar
  20. 20.
    U. Montali, M. Del Tacca, C. Bernardini, D. Segnini, and G. Solaini,Drugs Explt. Clin. Res. 11, 219 (1985).Google Scholar
  21. 21.
    R. G. Canada, W. Saway, and E. ThompsonBiochem. Biophys. Res. Commun. 151, 679 (1988).PubMedCrossRefGoogle Scholar
  22. 22.
    K. J. A. Davis, and J. H. DoroshowJ. Biol. Chem. 261, 3060 (1986).Google Scholar
  23. 23.
    H. NohlBiochem. Pharmacol. 37, 2633 (1988).PubMedCrossRefGoogle Scholar
  24. 24.
    G. PowisFree Radical Biol. Med. 6, 63 (1989).CrossRefGoogle Scholar
  25. 25.
    H. Hida, C. Coudray, J. Calop, and A. Favier,Biol Trace Element Res. accepted for publication (1994).Google Scholar
  26. 26.
    C. Coudray, S. Mouhiedine, M. J. Richard, J. Arnaud, J. de Leiris, and A. FavierBasic Res. Cardiol. 87, 173 (1992).PubMedCrossRefGoogle Scholar
  27. 27.
    P. Sangeetha, U. N. Das, R. Koratkar, and P. SuriyaprabhaFree Radic Biol. Med. 8, 19 (1990).CrossRefGoogle Scholar

Copyright information

© Humana Press Inc. 1995

Authors and Affiliations

  • Michel Faber
    • 1
  • Charles Coudray
    • 1
  • Hassan Hida
    • 1
  • Mireille Mousseau
    • 2
  • Alain Favier
    • 1
    • 3
  1. 1.Laboratoire de Biochimie CHôpital Albert MichallonGrenoble CedexFrance
  2. 2.Service d’OncologieHôpital Albert MichallonGrenoble CedexFrance
  3. 3.Faculté de Médecine et de PharmacieGroupe de Recherche sur les Pathologies Oxydatives (Grepo)La TroncheFrance

Personalised recommendations